Last reviewed · How we verify
Racemic Cloprostenol (CLOPROSTENOL)
At a glance
| Generic name | CLOPROSTENOL |
|---|---|
| Target | Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1,PHASE2)
- Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE1)
- Treatment of Hypopigmented Scars With Bimatoprost (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Racemic Cloprostenol CI brief — competitive landscape report
- Racemic Cloprostenol updates RSS · CI watch RSS